OCI-LY3

OCI-LY3|/OCI-LY3|细胞系/OCI-LY3|细胞株/OCI-LY3|人弥漫大B细胞淋巴瘤细胞

Cell line name OCI-Ly3

Synonyms OCI-LY3; OCI-ly3; OCI-LY-3; Oci-Ly-3; OCI-Ly 3; OCILY-3; OCI-Ly03; OCI Ly3; OCILY3; Ly3; LY3

Accession CVCL_8800

Resource Identification Initiative To cite this cell line use: OCI-Ly3 (RRID:CVCL_8800)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

From: Ontario Cancer Institute (OCI); Toronto; Canada.

Population: Caucasian.

Doubling time: ~24 hours (DSMZ=ACC-761).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Genome sequenced.

Omics: H3K9ac ChIP-seq epigenome analysis.

Omics: miRNA expression profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Caution: A cell line, now termed GNE-587170 (Cellosaurus=CVCL_AT69), was mistakenly distributed by OCI to a number of groups under the designation OCI-Ly-3, the origin of that cell line is now known.

Misspelling: Ocl-Ly3; GEO=GSM3150251.

Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.

Sequence variations

Gene fusion; HGNC; 5477; IGH + HGNC; 11242; SPIB; Name(s)=IGH-SPIB (PubMed=31160637; DSMZ=ACC-761).

Mutation; HGNC; 16393; CARD11; Simple; p.Leu251Pro (c.752T>C) (L244P); ClinVar=VCV001017661; Zygosity=Homozygous (PubMed=18323416; DepMap=ACH-000158).

Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Homozygous (PubMed=21179087; PubMed=23321251; DepMap=ACH-000158).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*01:01,03:01

HLA-B B*08:01,08:01

HLA-C C*07:01,07:01

 

Source: DSMZCellDive=ACC-761

Class I

HLA-A A*01:01:01,03:01:01

HLA-B B*08:01:01,08:01:01

HLA-C C*07:01:01,07:01:01

Class II

HLA-DP DPA1*02:01:02,02:01:02

DPB1*01:01:01,01:01:01

HLA-DQ DQA1*05:01:01,05:01:01

DQB1*02:01:01,02:01:01

HLA-DR DRA*01:02:02,01:02:02

DRB1*03:01:01,03:01:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0.02

Native American 0

East Asian, North 4.08

East Asian, South 0

South Asian 0

European, North 65.42

European, South 30.48

Disease Diffuse large B-cell lymphoma activated B-cell type (NCIt: C36081)

Diffuse large B-cell lymphoma (ORDO: Orphanet_544)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Sex of cell Male

Age at sampling 52Y

Category Cancer cell line

STR profile Source(s): DSMZ=ACC-761

 

Markers:

Amelogenin X,Y

CSF1PO 10,12

D2S1338 24

D3S1358 14

D5S818 12

D7S820 11,12

D8S1179 12,13

D13S317 11

D16S539 11,12

D18S51 17

D19S433 13,15

D21S11 28

FGA 21,23

Penta D 9

Penta E 7,11

TH01 7,9.3

TPOX 8,12

vWA 17

PubMed=15122589; DOI=10.1002/ijc.20170

Liggins A.P., Guinn B.A., Hatton C.S., Pulford K., Banham A.H.

Serologic detection of diffuse large B-cell lymphoma-associated antigens.

Int. J. Cancer 110:563-569(2004)

 

PubMed=18323416; DOI=10.1126/science.1153629

Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W.-H., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Chan W.-C., Staudt L.M.

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Science 319:1676-1679(2008)

 

PubMed=19278952; DOI=10.1182/blood-2009-01-202028; PMCID=PMC3401058

Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T.

Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.

Blood 113:6681-6690(2009)

 

PubMed=20054396; DOI=10.1038/nature08638; PMCID=PMC2845535

Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. 3rd, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Nature 463:88-92(2010)

 

PubMed=20628145; DOI=10.1182/blood-2010-05-282780; PMCID=PMC2995356

Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R., Kutok J.L., Shipp M.A.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Blood 116:3268-3277(2010)

 

PubMed=20889926; DOI=10.1182/blood-2010-06-290437; PMCID=PMC3037744

Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E., Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.

Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways.

Blood 117:200-210(2011)

 

PubMed=21179087; DOI=10.1038/nature09671; PMCID=PMC5024568

Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H., Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. 3rd, Romesser P.B., Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Staudt L.M.

Oncogenically active MYD88 mutations in human lymphoma.

Nature 470:115-119(2011)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=23257783; DOI=10.1038/leu.2012.367

Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.

MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.

Leukemia 27:1381-1390(2013)